• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a formulation comprising: - an aerosolization support; - nicotine; characterized in that at least 5% of said nicotine is in the form of R enantiomer. In one embodiment, the formulation according to the invention is characterized in that at least 10% of said nicotine is under enantiomeric form R.
    公开号:FR3047641A1
    申请号:FR1651181
    申请日:2016-02-12
    公开日:2017-08-18
    发明作者:Vincent Bonnarme；Antoine Piccirilli
    申请人:LABORATOIRES CERES；
    IPC主号:
    专利说明:

    FORMULATION COMPRISING AEROSOLIZATION SUPPORT
    AND NICOTINE R
    The present invention relates to the field of smoking cessation.
    The present invention relates to the technical field of tobacco products such as cigarettes, and more particularly to tobacco substitutes, and substitutes for traditional cigarettes, such as electronic cigarettes.
    More specifically, this invention relates to a composition comprising nicotine in the form of enantiomer R, liquid or solid composition on a substrate for example plant.
    Traditional cigarettes consist of a small paper cylinder containing minced and processed tobacco leaves, the cigarette may have at one of its ends a filter. A traditional cigarette can be rolled by hand, or manufactured industrially.
    [0005] Cigarette smoke contains many toxic substances, of which at least 60 are carcinogenic (tar, methanol, arsenic, ammonia, lead, etc.). The consumption of traditional cigarettes causes the death of about 6 million people worldwide each year, as well as many cardiovascular, cancerous and other diseases. (source WHO 2015).
    For all these reasons, legislations on traditional cigarettes are becoming increasingly restrictive in the world, whether it is selling, places of consumption, design, or even composition.
    As regards composition, tobacco companies are increasingly led to remove dangerous substances from their cigarettes, of which nicotine is a part.
    For example, in France, several successive laws were intended to limit the latitude that tobacco companies have. By 1964, manufacturers had to print a warning message about the toxicity of tobacco on each package. In 1971, advertising was banned on radio and television. Then, anti-smoking legislation was defined by the Veil Act of 1976, and by the Evin Act of 1991. The purpose of these two laws is to protect non-consumers from passive smoking, the Evin Law also prohibits all advertising and establishes the ban on smoking in all enclosed public places such as shopping centers, railway stations, airports. In addition, in the late 2000s, smoking was banned in public places, such as bars and clubs.
    In the context of the use of a traditional cigarette, the transfer of tobacco nicotine in the vicinity of the pulmonary alveoli is achieved by the inclusion of nicotine in particles, a portion of which will be conveyed to alveoli, exchange site between the gaseous medium and the blood medium.
    It is known that conventional cigarettes pose health risks to smokers and those around them, so there is a need: - to make them as toxic as possible; - to provide means of smoking cessation, in order to limit their consumption at the level of the population.
    When a smoker decides to stop the traditional cigarette without any treatment or medical follow-up, the success rate is very low, of the order of 3 to 5% at six months.
    In this context, a set of methods have been developed to increase the success rate of smoking cessation.
    First, some smokers use a treatment based on particular active ingredients.
    A number of pharmaceutical specialties may be mentioned, for example ZYBAN® (bupropion), CHAMPIX® (varenicline) or the well-known patches containing nicotine.
    Another strategy consists of behavioral and cognitive therapies and its derivatives. This has the principle of training the smoker to control his desires. This approach is especially used in first intention in pregnant women.
    [00016] Finally, other strategies exist, more confidential: acupuncture, hypnosis, mesotherapy, homeopathy, auriculotherapy, etc.
    Most of the time, the smoking cessation methods are classified according to whether or not they have a pharmacological treatment. In addition, an important aspect of smoking cessation is related to gestures, psychological aspects, non-pharmacological.
    In this context, some withdrawal strategies take into account the gestural aspect, offering devices that resemble near or far to a traditional cigarette, which mimic the appearance of traditional cigarettes.
    [00019] Some applications relate to devices without batteries mimicking the appearance of a traditional cigarette, these devices have most of the time an element included within them which, itself, includes nicotine or an equivalent having a other structure.
    In the application WO 2013/090410, a smoking cessation device simulating in particular the sensation obtained with a traditional cigarette is disclosed. This application relates to a device without a battery, the components of the disclosed device evaporate, without heating, during the suction caused by the smoking user. A similar device has also been disclosed in WO 2015/017761.
    Other approaches of the prior art relate to what is now commonly called "electronic cigarettes", or even "e-cigarettes", this is particularly the case of the WO application 2014/590079, the disclosed device is an electronic cigarette comprising nicotine as well as an "ion pairing agent".
    The e-cigarette comprises, schematically, three main elements: - a power supply means; - a cartridge or a reservoir; an atomizer.
    Regarding the power supply means, it may be a battery, rechargeable or not.
    Regarding the cartridge or the reservoir he or she comprises a liquid commonly called "e-liquid" or "e-cigarette liquid", "liquid for e-cigarette". In the context of the present application, the term "vaporizable liquid composition" is the most encompassing term and includes e-liquids. E-liquids traditionally comprise one or more solvents (it may for example be propylene glycol and / or glycerol and / or water), one or more flavor (s) and / or dye (s) and / or other additives, and sometimes nicotine (usually 0 to 20 mg / ml).
    Some variants with regard to the composition have been proposed in the prior art. The application WO 2015/101760 in the name of LABORATOIRES CERES discloses the use of a solvent in substitution of propylene glycol, the latter solvent being 1,3-propanediol.
    1,3-propanediol allows in some embodiments to overcome further the use of glycerol.
    Regarding the atomizer, the latter converts the liquid fog / steam simulating smoke, the latter may in particular be made of a heating resistor. It can be integrated in the e-liquid cartridge, in case a cartridge is used. A small valve sensitive to depression caused by inspiration or a manually triggered contactor allows the battery supply of the atomizer.
    In addition to these three main elements, the electronic cigarette may include other elements: indicator light mimicking combustion, display screen (to inform about the degree of charge of the battery, etc.), adjustment wheel the intensity of the steam, etc.
    [00029] There is a need to provide e-cigarettes having better weaning qualities for the smoker and, if possible, reduced toxicity.
    This need also exists with regard to other devices for replacing cigarettes.
    It may also be mentioned, among the devices mimicking traditional cigarettes, cigarettes without tobacco, sold for example under the trade name IMTB®. In addition to the controversies surrounding the dangerous nature of non-smoking cigarettes, smokers are often described as having poor organoleptic characteristics.
    The nicotine molecule has an asymmetric carbon, and therefore two isomers R and S. In tobacco, and therefore in traditional cigarettes including tobacco, nicotine R is very minor compared to nicotine S (much less than 5%).
    [00033] In the publication "Based-Catalyzed Racemization of Nicotine" (Heterocycles, 19, 11, 1982), a method of racemizing nicotine, capable of transforming nicotine S (of natural origin) into nicotine. R is described.
    In the US application 2003/082109 in the name of GORENSTEIN, a chewing gum comprising nicotine R is described.
    In the publication "Application of Nicotine and Enantiomers, Derivatives and Analogs in Neurodegenerative Disorders Therapy" (European Journal of Pharmacology, 563 (2007) 18-39), many uses of the enantiomers of nicotine in the context of therapies for prevention and / or care related to neurodegenerative diseases are described. Part V relates to the biological properties of nicotine R, and related perspectives. It is stated that numerous studies have established that the pharmacological effects of the R enantiomer are similar (qualitatively) but less important than those of the S enantiomer.
    In the application WO 2005/084126 in the name of FRIEDMAN, a smoking cessation device is described, it is stated that the nicotine may be nicotine R, this application is centered on a "sucking element", the device is intended to release nicotine in the mouth, there is no direct transfer of the device to a mucosa other than the oral mucosa.
    In the application WO 2014/174505, in the name of PERRIGO API LTD., A method of manufacturing nicotine comprising an enzymatic reduction is described, it is specified on page 1 that the nicotine R is less active and less toxic than the Nicotine S.
    In the application EP 0 568 208 in the name of REYNOLDS TOBACCO COMPANY, a treatment of neurodegenerative diseases by nicotine R is described.
    Thus no document of the prior art describes a composition for aerosolization of nicotine R.
    Finally, current e-liquids, when they include nicotine, include nicotine S.
    The smoke of a traditional cigarette gives the smoker a beneficial sensation in the throat, consisting of a tingle typically felt by the user during the passage of nicotine into the mouth. This sensation is commonly called "throat tingling", "throat scratching", or, in English, "throat hit", "throat scratch" or "throat impact".
    This effect is highly sought after by users of traditional cigarette substitutes or so-called lightweight products.
    In the case of the use of an electronic cigarette as in the case of the use of a traditional cigarette, the nicotine is absorbed in aerosol form, the aerosol particles may have different characteristics ( type of half-life, size, size distribution, they can be solid and / or liquid, etc.).
    A study comparing the characteristics of aerosol particles is available, this is the publication "Comparison of the aerosol of the electronic cigarette to that of ordinary cigarettes and shisha" (Journal of Respiratory Diseases (2013). 30, 752-757).
    In the context of the present application, the term "aerosol" is a set of solid and / or liquid particles, suspended in a gaseous medium. For example, haze or mist is an aerosol because the water droplets remain suspended in the air. The smoke of a chimney is also an aerosol because the liquid and solid particles remain in suspension in the gas resulting from the combustion. The tobacco smoke of a conventional cigarette is also an aerosol, since the particles remain in suspension in the gas resulting from the combustion. Finally, an e-cigarette vapor is also an aerosol because the droplets remain in suspension in the gas resulting from the vaporization of the e-liquid. On the other hand, the falling rain is not an aerosol because the drops do not stay in suspension. As a criterion of persistence, it may for example be considered that the particles of an aerosol must fall by less than 0.5 m / second.
    In the context of the present application, the term "aerosolization support" a support allowing, with or without energy input, to generate an aerosol. It may for example be a plant substrate such as tobacco (cigarette or even narghile). It can also be an e-cigarette liquid. When the aerosolization carrier is a plant substrate such as tobacco, it is an aerosolization carrier of the "degradable" type, it will be consumed. When the aerosolization carrier is an e-liquid, it is a "state change" aerosolization carrier (there are no or few chemical reactions, the aerosol is generated by the vaporization of the e-liquid).
    In the context of the present application, the term "formulation" a formulation that may include particular compounds, and may give rise to aerosolization. In particular, the term "formulation according to the invention" will be used for such formulations comprising nicotine R. The term "conventional formulation" or "traditional" formulation for such formulations comprising nicotine S (isomer which is particularly present in cigarettes traditional and in current e-cigarette liquids), the traditional formulations are tobacco and e-cigarette liquids including nicotine R. Most of the time, it will be specified "traditional formulation including nicotine S" .
    In the context of the present application, when a formulation includes an aerosolization carrier and nicotine, said nicotine is expressly excluded from the term "aerosolization carrier".
    [00049] There is a need to provide more effective smoking cessation methods, preferably taking into account both aspects related to pharmacology (feeling of lack, etc.) and psychological aspects (devices having the appearance of a traditional cigarette, similar gestures, etc.).
    Surprisingly, it has been demonstrated by the applicant that nicotine R, in combination with an aerosolization support, said aerosolization support may for example be a liquid vaporizable composition of the e-liquid type or a plant substrate, such as tobacco, had the effect of causing the smoker to have a lower desire to smoke a traditional cigarette or an e-cigarette including nicotine S thereafter.
    Without wishing to be bound by any explanation, it seems that the receptors on which the nicotine S, particularly in the airways, are desensitized by nicotine R. This calls for two remarks: the effect felt by the nicotine R on the airways (throat hit) is less than the effect of nicotine S; once brought into contact with nicotine R, the airways are less sensitive to nicotine S for a certain period.
    In practice, this is of great interest to the extent that the smoker, alternating nicotine R and S, will become progressively less dependent on nicotine S, which will not cause him the same effect on the airways.
    In addition, the psychological aspects (gestures, etc.) are maintained, in order to help the smoker to abandon his addiction gradually.
    Finally, nicotine R has a lower toxicity (the toxicity is lowered by the order of 60% to 70% between nicotine S and nicotine R).
    The invention relates to a formulation comprising: an aerosolization support; - nicotine; characterized in that at least 5% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 10% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 20% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 40% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 60% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 80% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that at least 95% of said nicotine is in the form of R enantiomer.
    In one embodiment, the formulation according to the invention is characterized in that said aerosolization support is a state of change aerosolization support.
    In one embodiment, the formulation according to the invention is characterized in that said aerosolization support is a liquid vapori sand composition.
    In one embodiment, the formulation according to the invention is characterized in that said vaporization is carried out by a heat of between 10 ° C and 200 ° C.
    In one embodiment, the formulation according to the invention is characterized in that said vaporization is operated by a heat of between 30 ° C and 150 ° C.
    In one embodiment, the formulation according to the invention is characterized in that said vaporization is operated by a heat of between 50 ° C and 90 ° C.
    In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said liquid vapori sand composition is between 1 mg / ml and 40 mg / ml.
    In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said vaporizable liquid composition is between 5 mg / ml and 30 mg / ml.
    In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said vaporizable liquid composition is between 5 mg / ml and 20 mg / ml.
    In one embodiment, the formulation according to the invention is characterized in that the said vaporizable liquid composition comprises at least one solvent chosen from the group consisting of glycerol, propylene glycol, ethanol, diglycerol, phosphine triglycerol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,3-propanediol and mixtures thereof.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least one solvent selected from the group consisting of glycerol, propylene glycol and 1,3-propanediol.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least glycerol.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least diglycerol.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least one solvent selected from the group consisting of propylene glycol, and 1,3-propanediol.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least propylene glycol.
    In one embodiment, the formulation according to the invention is characterized in that said vaporizable liquid composition comprises at least 1,3-propanediol.
    In one embodiment, the formulation according to the invention is characterized in that it further comprises at least one nicotine substitute other than nicotine.
    In one embodiment, the formulation according to the invention is characterized in that said aerosolization carrier is a degradable aerosolization carrier.
    In one embodiment, the formulation according to the invention is characterized in that said aerosolization support is a plant substrate.
    In one embodiment, the formulation according to the invention is characterized in that said aerosolization support is tobacco.
    In one embodiment, the formulation according to the invention is characterized in that the weight content of said nicotine R in said tobacco is between 0.01 and 5% [00082] In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said tobacco is between 0.01 and 0.1%.
    In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said tobacco is between 0.05 and 0.5%.
    In one embodiment, the formulation according to the invention is characterized in that the concentration of said nicotine R in said tobacco is between 0.1 and 0.2%.
    In one embodiment, the formulation according to the invention is characterized in that it further comprises at least one nicotine substitute other than nicotine.
    In one embodiment, the formulation according to the invention is characterized in that the said at least one nicotine substitute is chosen from the group consisting of vitamin C, the alkaloids, the pepper extracts, the extracts of chili, hydroxy acids, organic derivatives comprising a pyridine and / or pyrrolidine unit.
    [00087] Electronic cigarette, characterized in that it comprises a liquid vapor formulation according to the invention.
    [00088] Tank or electronic cigarette cartridge, characterized in that it comprises a vaporizable liquid formulation according to the invention.
    The invention also relates to a smoking cessation method in a person, characterized in that it comprises: at least one aerosolization step and then inhalation by said person of a formulation according to any one of the preceding claims. ; then - at least one aerosolization step and then inhalation by said person of a traditional formulation comprising nicotine S; said steps being separated by a time interval of at least 10 minutes.
    The invention also relates to a formulation according to the invention, intended to be used in smoking cessation, said formulation being aerosolized / inhaled before aerosolization / inhalation of a traditional formulation comprising nicotine S.
    The invention also relates to a formulation according to the invention, intended to be used in smoking cessation, said formulation being aerosolized / inhaled before aerosolization / inhalation of a traditional formulation comprising nicotine S, said aerosolizations / inhalation separated by a time interval of at least 10 minutes.
    The invention also relates to a packaging comprising at least two cigarettes, wherein: at least one cigarette is a cigarette comprising a formulation according to the invention. - at least one cigarette is a traditional cigarette.
    In one embodiment, the packaging according to the invention is characterized in that the at least one cigarette comprising a formulation according to the invention and the at least one traditional cigarette are not discernable visually by the smoker. average attention.
    EXAMPLES
    EXAMPLE 1 Sprayable Liquid Compositions Comprising Nicotine R According to the Invention The following liquid vaporizable compositions were prepared:
    Example 2: Influence of the desensitization caused by nicotine R on the effect produced by the subsequent intake of nicotine S.
    The desensitization caused by nicotine R on the effect produced by the subsequent intake of nicotine S was evaluated.
    The purpose of these tests is to demonstrate the inhibitory effect of nicotine R nicotine S addictive evaluated according to the feeling of the scratching effect in the throat.
    [00097] The test was conducted with 4 subjects, all vapoteurs or go p u uters / fu meurs.
    The electronic cigarette used is the following: Battery Eleaf i-stick TV 60W Clear Evod Wicker 2.2 ohms, power output, 7.3 V.
    The nicotine compositions R and / or S of the e-liquids (or aerosolizable liquid compositions) used are as follows:
    The preliminary conditions (preparation of the tests) are as follows:
    [000101] The e-liquid 1 (100% nicotine S) and the e-liquid 2 (100% nicotine R) were tested at first. E-liquid 1 (100% nicotine S, 5 puffs) provides a throat scratching force felt 9/10, while e-liquid 2 (100% nicotine R, 5 puffs) provides a feeling of scratching throat felt 0/10. Nicotine R therefore does not cause any scratching of the throat, unlike nicotine S.
    [000102] Desensitization tests were then conducted, as follows;
    [000103] Conclusion of the desensitization test: the desensitization induced by e-liquid 2 (100% nicotine R) is more pronounced than that induced by e-liquid 3 (50% nicotine R - 50% nicotine S), in the as the force of throat scratching felt during the subsequent soup e-liquid 1 (100% nicotone S) is lower.
    This demonstrates that nicotine R desensitizes more than nicotine S.
    权利要求:
    Claims (12)
    [1" id="c-fr-0001]
    1. Formulation comprising: - an aerosolization support; - nicotine; characterized in that at least 5% of said nicotine is in the form of R enantiomer.
    [2" id="c-fr-0002]
    2. Formulation according to claim 1, characterized in that said aerosolization support is a liquid vaporizable vaporization composition.
    [3" id="c-fr-0003]
    3. Formulation according to claim 2, characterized in that said vaporization is operated by a heat of between 10 ° C and 200 ° C.
    [4" id="c-fr-0004]
    4. Formulation according to any one of claims 1 to 3, characterized in that. the concentration of said nicotine R in said vaporizable liquid composition is between 1 mg / ml and 40 mg / ml.
    [5" id="c-fr-0005]
    5. Formulation according to any one of claims 2 to 4, characterized in that said vaporizable liquid composition comprises at least one solvent selected from the group consisting of glycerol, propylene glycol, ethanol, diglycerol, triglycerol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, from 1 3-propanediol and mixtures thereof.
    [6" id="c-fr-0006]
    6. Formulation according to any one of claims 2 to 5, characterized in that said vaporizable liquid composition comprises at least one solvent selected from the group consisting of propylene glycol, and 1,3-propanediol.
    [7" id="c-fr-0007]
    7. Formulation according to claim 1, characterized in that said aerosolization carrier is a degradable aerosolization carrier.
    [8" id="c-fr-0008]
    8. Formulation according to claim 7, characterized in that said aerosolization carrier is plant substrate.
    [9" id="c-fr-0009]
    9. Formulation according to any one of the preceding claims, characterized in that it further comprises at least one nicotine substitute different from nicotine.
    [10" id="c-fr-0010]
    10. Electronic cigarette, characterized in that it comprises a vaporizable liquid formulation according to any one of claims 2 to 6
    [11" id="c-fr-0011]
    11. Tank or electronic cigarette cartridge, characterized in that it comprises a vaporizable liquid formulation according to any one of claims 2 to 6.
    [12" id="c-fr-0012]
    A formulation according to any of claims 1 to 9 for use in smoking cessation.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2561856C1|2015-09-10|Method and device for imitation of chemosensor smoking sensations
    Knorst et al.2014|The electronic cigarette: the new cigarette of the 21st century?
    US5893371A|1999-04-13|Non-nicotine smoking cessation aid
    US20050236006A1|2005-10-27|Smoking cessation devices, methods of use and methods of conducting business therewith
    FR3047641A1|2017-08-18|FORMULATION COMPRISING AN AEROSOLIZATION MEDIUM AND NICOTINE R
    Kong et al.2017|A call to end the epidemic of adolescent E-cigarette use
    CH702775B1|2011-08-15|soft gelatin tablets containing nicotine and preparation process.
    KR101257828B1|2013-04-29|Composition of antismoking aid containing damascone
    Slade1993|Nicotine delivery devices
    US20160095816A2|2016-04-07|Article and methods for oral self-administration of nicotine
    Aicher et al.2016|Electronic cigarettes
    JP2022506067A|2022-01-17|Aerosolizable formulations
    WO2015067773A1|2015-05-14|Ethanol-based plant macerate
    US5383478A|1995-01-24|Low tar and low nicotine cigarette adapted to provide enhanced smoking satisfaction
    Fowles et al.2001|Chemical factors influencing the addictiveness and attractiveness of cigarettes in New Zealand
    Shantakumari et al.2015|Cigarette alternatives: Are they safe?
    Quan2016|Electronic Cigarette and Nicotine Toxicity
    US20130287704A1|2013-10-31|Article and methods for oral self-administration of nicotine
    Del Ciampo et al.2019|Adolescents, e-cigarettes and nicotine: a dangerous interaction
    Majewski et al.2020|Electronic cigarettes and their effects on human health
    Rao et al.2017|E-cigarettes in India-An invite to oral cancer
    Ejaz et al.2017|E-Cigarettes: Harmless substitute to conventional smoking or a devil in disguise?
    WO2021214491A1|2021-10-28|Aerosolisable formulation
    World Health Organization et al.2006|Tobacco: deadly in any form or disguise
    Robinson2021|9 Tobacco and health
    同族专利:
    公开号 | 公开日
    FR3047641B1|2021-10-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS56113286A|1980-02-08|1981-09-07|Japan Tobacco & Salt Public|Tobacco smoking taste imparting method|
    JPS5871893A|1981-10-26|1983-04-28|Japan Tobacco Inc|Preparation of r-nicotine|
    AU4146985A|1985-04-22|1986-10-30|Advanced Tobacco Products Inc.|Vaporisable nicotine composition|
    US4793366A|1985-11-12|1988-12-27|Hill Ira D|Nicotine dispensing device and methods of making the same|
    US4830028A|1987-02-10|1989-05-16|R. J. Reynolds Tobacco Company|Salts provided from nicotine and organic acid as cigarette additives|
    WO2015183801A1|2014-05-27|2015-12-03|R. J. Reynolds Tobacco Company|Nicotine salts, co-crystals, and salt co-crystal complexes|IT201700106031A1|2017-09-22|2019-03-22|Renzo Luciano Cattaneo|Creation of a liquid formulation for the rapid addition of nicotine and the reduction of harmful emissions of liquids for electronic cigarettes|
    CN110506978A|2019-09-11|2019-11-29|深圳多客技术有限公司|A kind of electronic cigarette oil solvent, electronic cigarette tobacco tar and preparation method comprising it|
    CN110916241A|2019-11-20|2020-03-27|许达勇|Nicotine aerosol and preparation method thereof|
    法律状态:
    2017-01-24| PLFP| Fee payment|Year of fee payment: 2 |
    2017-08-18| PLSC| Publication of the preliminary search report|Effective date: 20170818 |
    2018-02-16| PLFP| Fee payment|Year of fee payment: 3 |
    2020-01-31| PLFP| Fee payment|Year of fee payment: 5 |
    2021-02-20| PLFP| Fee payment|Year of fee payment: 6 |
    2022-02-26| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1651181A|FR3047641B1|2016-02-12|2016-02-12|FORMULATION INCLUDING AEROSOLISATION SUPPORT AND NICOTINE R|FR1651181A| FR3047641B1|2016-02-12|2016-02-12|FORMULATION INCLUDING AEROSOLISATION SUPPORT AND NICOTINE R|
    [返回顶部]